publication date: Mar. 10, 2017
Lynch steps in as CSO at Bristol-Myers Squibb
Thomas Lynch was named chief scientific officer at Bristol-Myers Squibb.
Lynch served as chairman and CEO of Massachusetts General Physicians Organization and as a member of the MGH Board from 2015 to 2017. He also previously served as a director on Bristol-Myer Squibb’s board from 2013-2017.
Before his roles as chairman and CEO at MGH, Tom served as the director of Yale Cancer Center and was the Richard and Jonathan Sackler Professor of Internal Medicine at the Yale School of Medicine from 2009 to 2015. He also served as the Physician in Chief of Smilow Cancer Hospital, Yale New Haven from 2009 to 2015.
Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. While at MGH in 2004, Lynch was part of the team credited with the significant discovery that certain genetic mutations in lung cancer patients caused therapies to work for some individuals and not for others.
Pharma companies collaborate in NCCN’s multi-industry project
The NCCN Oncology Research Program has awarded grants for its first-ever multi-industry collaborative project, soliciting investigator-initiated proposals to research the effectiveness of Boehringer Ingelheim’s afatinib in combination with other drugs to treat lung and head and neck cancers.
The National Comprehensive Cancer Network has funded three studies in its first multi-industry collaborative research project in which Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. are collaborating with NCCN to study combination therapeutic agents in lung cancer and head and neck cancers.
The following studies were awarded funding through NCCN … Continue reading Lynch steps in as CSO at Bristol-Myers Squibb
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.